Uricosuric effect of fenofibrate in healthy volunteers.
The uricosuric properties of a single oral dose (300 mg) of fenofibrate, or isopropyl-[4'-(p-chlorobenzoyl)-2-phenoxy-2-methyl] propionate (LF 178), a new hypolipidemic drug, have been investigated versus placebo, benzbromarone, with and without urine alkalinization, in ten normouricemic male volunteers, following a crossover design. Twofold increased uric acid clearance values were obtained after fenofibrate and fourfold increased values after benzbromarone. The ratio urinary uric acid/urinary creatinine (UUA/UCr) was enhanced after fenofibrate and benzbromarone versus placebo. The urine alkalinization with fenofibrate intake did increase this ratio to a higher extent.
D000328:Adult; D001553:Benzbromarone / Q000494:pharmacology; D011345:Fenofibrate / Q000494:pharmacology*; D006801:Humans; D008297:Male; D011422:Propionates / Q000494:pharmacology*; D014528:Uricosuric Agents
D011422:Propionates; D014528:Uricosuric Agents; D001553:Benzbromarone; D011345:Fenofibrate